Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1985 May;75(5):1584–1590. doi: 10.1172/JCI111864

Pulsatile growth hormone secretion in normal man during a continuous 24-hour infusion of human growth hormone releasing factor (1-40). Evidence for intermittent somatostatin secretion.

M L Vance, D L Kaiser, W S Evans, R Furlanetto, W Vale, J Rivier, M O Thorner
PMCID: PMC425499  PMID: 2860126

Abstract

Growth hormone (GH) secretory patterns were studied in a patient with ectopic growth hormone releasing factor (GRF) secretion and in normal men given continuous infusions of human growth hormone releasing factor (1-40)-OH (hGRF-40). In the patient with ectopic GRF secretion, GH secretion was pulsatile despite continuously elevated immunoreactive GRF levels. To determine if pulsatile GH secretion is maintained in normal subjects, we administered to six healthy young men vehicle or hGRF-40, 2 ng/kg per min, for 24 h and gave a supramaximal intravenous bolus dose of hGRF-40, 3.3 micrograms/kg, after 23.5 h of infusion. hGRF-40 infusion resulted in greater GH secretion than did vehicle infusion and pulsatile GH secretion was maintained throughout hGRF-40 infusion. During the 23.5 h of vehicle infusion, total GH secretion (microgram; mean +/- SEM) was 634 +/- 151 compared with 1,576 +/- 284 during hGRF-40 infusion (P = 0.042). The GH response to the intravenous bolus of hGRF-40 was greater after vehicle infusion than after hGRF-40 infusion; 877 +/- 170 and 386 +/- 125 micrograms of GH was secreted after the bolus on vehicle and hGRF-40 days, respectively (P = 0.015). The total amount of GH secreted during the 25.5 h of the two study days was not different; 1,504 +/- 260 and 1,952 +/- 383 micrograms were secreted during vehicle and hGRF-40 days, respectively (P = 0.36). Not only was pulsatile GH secretion maintained during hGRF-40 infusion, but there was augmentation of naturally occurring GH pulses, which is in contrast to the effect of gonadotropin-releasing hormone on gonadotropin secretion. We suggest that GH pulses are a result of GRF secretion that is associated with a diminution or withdrawal of somatostatin secretion.

Full text

PDF
1584

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abe H., Molitch M. E., Van Wyk J. J., Underwood L. E. Human growth hormone and somatomedin C suppress the spontaneous release of growth hormone in unanesthetized rats. Endocrinology. 1983 Oct;113(4):1319–1324. doi: 10.1210/endo-113-4-1319. [DOI] [PubMed] [Google Scholar]
  2. Berelowitz M., Firestone S. L., Frohman L. A. Effects of growth hormone excess and deficiency on hypothalamic somatostatin content and release and on tissue somatostatin distribution. Endocrinology. 1981 Sep;109(3):714–719. doi: 10.1210/endo-109-3-714. [DOI] [PubMed] [Google Scholar]
  3. Bilezikjian L. M., Vale W. W. Chronic exposure of cultured rat anterior pituitary cells to GRF causes partial loss of responsiveness to GRF. Endocrinology. 1984 Nov;115(5):2032–2034. doi: 10.1210/endo-115-5-2032. [DOI] [PubMed] [Google Scholar]
  4. Bremner W. J., Paulsen C. A. Two pools of luteinizing hormone in the human pituitary: evidence from constant administration of luteinizing hormone-releasing hormone. J Clin Endocrinol Metab. 1974 Nov;39(5):811–815. doi: 10.1210/jcem-39-5-811. [DOI] [PubMed] [Google Scholar]
  5. Caro J. F., Woolf P. D. Pituitary-ovarian axis responsivity to prolonged gonadotropin-releasing hormone infusion in normal and hyperprolactinemic women. J Clin Endocrinol Metab. 1980 Jun;50(6):999–1004. doi: 10.1210/jcem-50-6-999. [DOI] [PubMed] [Google Scholar]
  6. Clayton R. N. Gonadotropin-releasing hormone modulation of its own pituitary receptors: evidence for biphasic regulation. Endocrinology. 1982 Jul;111(1):152–161. doi: 10.1210/endo-111-1-152. [DOI] [PubMed] [Google Scholar]
  7. Copeland K. C., Underwood L. E., Van Wyk J. J. Induction of immunoreactive somatomedin C human serum by growth hormone: dose-response relationships and effect on chromatographic profiles. J Clin Endocrinol Metab. 1980 Apr;50(4):690–697. doi: 10.1210/jcem-50-4-690. [DOI] [PubMed] [Google Scholar]
  8. Frohman L. A., Thominet J. L., Webb C. B., Vance M. L., Uderman H., Rivier J., Vale W., Thorner M. O. Metabolic clearance and plasma disappearance rates of human pancreatic tumor growth hormone releasing factor in man. J Clin Invest. 1984 May;73(5):1304–1311. doi: 10.1172/JCI111333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Furlanetto R. W. Pitfalls in the somatomedin-C radioimmunoassay. J Clin Endocrinol Metab. 1982 May;54(5):1084–1086. doi: 10.1210/jcem-54-5-1084. [DOI] [PubMed] [Google Scholar]
  10. Furlanetto R. W., Underwood L. E., Van Wyk J. J., D'Ercole A. J. Estimation of somatomedin-C levels in normals and patients with pituitary disease by radioimmunoassay. J Clin Invest. 1977 Sep;60(3):648–657. doi: 10.1172/JCI108816. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. MacGillivray M. H., Frohman L. A., Doe J. Metabolic clearance and production rates of human growth hormone in subjects with normal and abnormal growth. J Clin Endocrinol Metab. 1970 May;30(5):632–638. doi: 10.1210/jcem-30-5-632. [DOI] [PubMed] [Google Scholar]
  12. Patel Y. C. Growth hormone stimulates hypothalamic somatostatin. Life Sci. 1979 Apr 23;24(17):1589–1593. doi: 10.1016/0024-3205(79)90020-1. [DOI] [PubMed] [Google Scholar]
  13. Rosenthal S. M., Schriock E. A., Kaplan S. L., Guillemin R., Grumbach M. M. Synthetic human pancreas growth hormone-releasing factor (hpGRF1-44-NH2) stimulates growth hormone secretion in normal men. J Clin Endocrinol Metab. 1983 Sep;57(3):677–679. doi: 10.1210/jcem-57-3-677. [DOI] [PubMed] [Google Scholar]
  14. Tannenbaum G. S. Evidence for autoregulation of growth hormone secretion via the central nervous system. Endocrinology. 1980 Dec;107(6):2117–2120. doi: 10.1210/endo-107-6-2117. [DOI] [PubMed] [Google Scholar]
  15. Tannenbaum G. S., Ling N. The interrelationship of growth hormone (GH)-releasing factor and somatostatin in generation of the ultradian rhythm of GH secretion. Endocrinology. 1984 Nov;115(5):1952–1957. doi: 10.1210/endo-115-5-1952. [DOI] [PubMed] [Google Scholar]
  16. Thorner M. O., Frohman L. A., Leong D. A., Thominet J., Downs T., Hellmann P., Chitwood J., Vaughan J. M., Vale W. Extrahypothalamic growth-hormone-releasing factor (GRF) secretion is a rare cause of acromegaly: plasma GRF levels in 177 acromegalic patients. J Clin Endocrinol Metab. 1984 Nov;59(5):846–849. doi: 10.1210/jcem-59-5-846. [DOI] [PubMed] [Google Scholar]
  17. Thorner M. O., Perryman R. L., Cronin M. J., Rogol A. D., Draznin M., Johanson A., Vale W., Horvath E., Kovacs K. Somatotroph hyperplasia. Successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone-releasing factor. J Clin Invest. 1982 Nov;70(5):965–977. doi: 10.1172/JCI110708. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Thorner M. O., Rivier J., Spiess J., Borges J. L., Vance M. L., Bloom S. R., Rogol A. D., Cronin M. J., Kaiser D. L., Evans W. S. Human pancreatic growth-hormone-releasing factor selectively stimulates growth-hormone secretion in man. Lancet. 1983 Jan 1;1(8314-5):24–28. doi: 10.1016/s0140-6736(83)91563-5. [DOI] [PubMed] [Google Scholar]
  19. Vance M. L., Borges J. L., Kaiser D. L., Evans W. S., Furlanetto R., Thominet J. L., Frohman L. A., Rogol A. D., MacLeod R. M., Bloom S. Human pancreatic tumor growth hormone-releasing factor: dose-response relationships in normal man. J Clin Endocrinol Metab. 1984 May;58(5):838–844. doi: 10.1210/jcem-58-5-838. [DOI] [PubMed] [Google Scholar]
  20. Vance M. L., Borges J. L., Kaiser D. L., Evans W. S., Furlanetto R., Thominet J. L., Frohman L. A., Rogol A. D., MacLeod R. M., Bloom S. Human pancreatic tumor growth hormone-releasing factor: dose-response relationships in normal man. J Clin Endocrinol Metab. 1984 May;58(5):838–844. doi: 10.1210/jcem-58-5-838. [DOI] [PubMed] [Google Scholar]
  21. Vance M. L., Kaiser D. L., Evans W. S., Thorner M. O., Furlanetto R., Rivier J., Vale W., Perisutti G., Frohman L. A. Evidence for a limited growth hormone (GH)-releasing hormone (GHRH)-releasable quantity of GH: effects of 6-hour infusions of GHRH on GH secretion in normal man. J Clin Endocrinol Metab. 1985 Feb;60(2):370–375. doi: 10.1210/jcem-60-2-370. [DOI] [PubMed] [Google Scholar]
  22. Wehrenberg W. B., Ling N., Böhlen P., Esch F., Brazeau P., Guillemin R. Physiological roles of somatocrinin and somatostatin in the regulation of growth hormone secretion. Biochem Biophys Res Commun. 1982 Nov 30;109(2):562–567. doi: 10.1016/0006-291x(82)91758-2. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES